New Drug Candidates for Diffuse Large B-cell Lymphoma

Request Number REQ0350364
Due Date October 23, 2017
Request for Proposal Details
RFP Title
New Drug Candidates for Diffuse Large B-cell Lymphoma
RFP Description

NineSigma, representing a global pharmaceutical company, seeks new drug candidates for diffuse large B-cell lymphoma (DLBCL) (low-molecular compounds and antibodies).


The client is a pharmaceutical company that is involved in research and development through manufacturing and sales, such as providing small molecule drugs and antibody drugs for solid tumors and hematological malignancies. The company positions oncology as one of the higher-priority areas in R&D and aims to create innovative new drugs for diseases with a low treatment satisfaction.


Although R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is used as a first-line treatment for DLBCL and exhibits a certain level of response rates, there are issues such as recurrence and acquisition of resistance and there is still a high unmet medical needs.


The client aims to develop drugs for treatment of DLBCL whose combinational effects with R-CHOP therapy can be expected or whose efficacy in patients resistant to R-CHOP therapy can be expected. The client has thus issued this open request in order to accelerate the clinical application of a new treatment drug in cooperation with potential organizations with promising candidate.


Respondents should submit proposals using the attached Response Template.


The client will review submitted proposals and possibly ask clarifying questions before selecting the most suitable candidates for collaboration. The client will select the best candidate(s) through evaluations. During the selection process, the client may execute non-disclosure agreements (NDA) with selected respondent(s), seek further information disclosure, and discuss specific development targets or potential opportunities. The client will execute necessary agreement(s) with the selected respondent(s) and move to the advanced development phase. Specifics of any collaboration will be determined through consultation with the concerned parties.


Key Success Criteria

Target drug seed and requirements 
The client anticipates new drug candidates that meet the following requirements.
  • Modality: small molecule compounds, antibodies
  • Should have supporting data on the following 2 points.
    • The synergistic/additive effect of the drug candidate combined with R-CHOP therapy, or the drug candidate is effective in patients resistant to R-CHOP therapy.
    • The percentage of patients with DLBCL in whom the efficacy can be expected.
  • Should be based on novel mechanisms different from existing drugs
    • However, known mechanisms may be accepted if a clear differentiation from existing drugs is possible.
  • Development level:
    • Should be the lead compounds at the discovery to optimization stage, or candidate compounds at non-clinical stage. 
      • Candidate substances should already have been obtained.
      • The mechanism of action needs to be clearly explained and it is desirable that the supporting data has already been obtained.
      • Drug efficacy should be confirmed in in vitro studies, desirably, it is confirmed in in vivo studies using animal models.

Approaches not of interest

The following approaches are not of interest:

  • Proposal for known substances with poor exclusivity property
  • Drug candidates other than low-molecular compounds and antibodies such as nucleic acid and cells


Preferred Collaboration types
  • Joint Development
  • Contract Research
  • Technology Licensing
Items to be submitted

Responses will use the Proposal Template which is linked to the “attachments“ shown at the bottom of the link <REQ0350364> and include the following items:

  • Overview of the new drug candidate (mechanism of action, superiority to existing drugs, etc.)
  • Biological data (pharmacological efficacy, safety, toxicity, pharmacokinetics, etc.)
  • Current R&D stage
  • Future research plans
  • Any requests concerning the collaboration
  • Collaborative research partnership status (presence or absence) for the proposed drug candidate
  • Status of intellectual property related to the proposed technology
  • Past research achievements (patents, research papers, research presentations, etc.)

Area of Interest
Request Priority